A detailed history of Woodline Partners LP transactions in Nektar Therapeutics stock. As of the latest transaction made, Woodline Partners LP holds 1,731,671 shares of NKTR stock, worth $1.61 Million. This represents 0.02% of its overall portfolio holdings.

Number of Shares
1,731,671
Previous 622,905 178.0%
Holding current value
$1.61 Million
Previous $772,000 191.58%
% of portfolio
0.02%
Previous 0.01%

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$1.11 - $1.48 $1.23 Million - $1.64 Million
1,108,766 Added 178.0%
1,731,671 $2.25 Million
Q2 2024

Aug 14, 2024

BUY
$0.9 - $1.83 $560,614 - $1.14 Million
622,905 New
622,905 $772,000
Q1 2022

May 16, 2022

SELL
$4.16 - $13.72 $4.1 Million - $13.5 Million
-986,617 Closed
0 $0
Q4 2021

Feb 14, 2022

BUY
$10.83 - $18.41 $10.7 Million - $18.2 Million
986,617 New
986,617 $13.3 Million

Others Institutions Holding NKTR

About NEKTAR THERAPEUTICS


  • Ticker NKTR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 187,404,992
  • Market Cap $174M
  • Description
  • Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in areas of unmet medical need in the United States and internationally. The company's products include Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in phase 3 clinical trial to treat metastatic melanoma, re...
More about NKTR
Track This Portfolio

Track Woodline Partners LP Portfolio

Follow Woodline Partners LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Woodline Partners LP, based on Form 13F filings with the SEC.

News

Stay updated on Woodline Partners LP with notifications on news.